Amylin Pharmaceuticals, Inc. announced that Michael Hanley, Ph.D. has joined the Company as vice president, discovery research. Dr. Hanley has served on the Scientific Advisory Board of Amylin since 1992 and for the last six months has served as a senior scientific advisor to the Company. Dr. Hanley will oversee Amylin's discovery research in the areas of research chemistry, in-vivo modeling and cell and molecular biology.
"Dr. Hanley brings an outstanding record of accomplishment in academic research and highly relevant experience in the development of research programs for biotechnology organizations," commented Daniel M. Bradbury, chief operating officer for Amylin Pharmaceuticals, Inc. "He has played an important role in guiding and refining the drug discovery capabilities of Amylin since the Company's formation, and we are pleased that he has agreed to lead our internal efforts to expand our pipeline of drug candidates to treat metabolic diseases."
From 1981 to 1997, Dr. Hanley held faculty positions at Imperial College, London, the Medical Research Council Laboratories, Cambridge, and the University of California at Davis, where he was Professor of Biological Chemistry.